The global protein glutamine gamma glutamyltransferase 2 market is anticipated to grow at a significant CAGR during the forecast period. TG2 is a ubiquitous enzyme. It physiologically exerts multiple functions that are mostly linked to matrix assembly and tissue repair. The major factor accelerating the growth of the market is the rising incidence of celiac disease across the globe. According to Beyond Celiac, celiac disease damages the villi of the small intestine while interfering with the absorption of nutrients from food. Additionally, an estimated 1 in 133 Americans or about 1% of the population has celiac disease. Further, it is estimated that the prevalence of this disease is more than 1% in the US. Moreover, as per the mass screening program of children in Italy, the prevalence of celiac disease is estimated to be 1.6%. Apart from this, the prevalence of the celiac disease is estimated at 1.99% of the population in Finland. It can affect men and women of all ages and races. Hence, the increasing prevalence of this disease is driving the growth of the market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/protein-glutamine-gamma-glutamyltransferase-2-market
Some major players in the market include GlaxoSmithKline plc, Catabasis Pharmaceuticals Inc., and Zedira GmbH, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2019, Avalon Ventures announced entering into a definitive agreement with GlaxoSmithKline (GSK) to acquire Sitari Pharmaceuticals by GSK. The acquisition was aimed to give rights to GSK of a novel treatment being developed by Sitari for celiac disease.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- GlaxoSmithKline plc, Catabasis Pharmaceuticals Inc., and Zedira GmbH, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Protein Glutamine Gamma Glutamyltransferase 2 Market Report by Segment
By Type
- CAT-5571
- ERW-1041E
- ZED-1227
- Others
By Application
- Clinic
- Hospital
- Others
A full report of Protein Glutamine Gamma Glutamyltransferase 2 Market is available at: https://www.omrglobal.com/industry-reports/protein-glutamine-gamma-glutamyltransferase-2-market
Protein Glutamine Gamma Glutamyltransferase 2 Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- GlaxoSmithKline plc
- Catabasis Pharmaceuticals Inc.
- Zedira GmbH
